CLCS Cell Source, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1569340 · Fiscal year ends 12/31
Financial factors as of 2025-03-31 (2025Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY3.8%
TTM EPS YoY12.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,516.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6,985.4%
Debt / equity—
Current ratio—
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-857.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 | FY20202020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | — | — | $1.94M | $1.27M | $834,943 |
| SG&A expense | $1.94M | $2.60M | $2.18M | $2.70M | $2.64M |
| Operating income | -$3.84M | -$4.33M | -$4.18M | -$4.02M | -$3.64M |
| Interest expense | — | — | — | $629,201 | $636,156 |
| Pretax income | -$4.51M | -$5.32M | -$5.17M | -$5.47M | -$4.56M |
| Income tax | — | — | — | — | $0 |
| Net income | -$4.51M | -$5.32M | -$5.17M | -$5.47M | -$4.56M |
| EPS (basic) | -0.14 | -0.17 | -0.18 | -0.19 | -0.19 |
| EPS (diluted) | -0.14 | -0.17 | -0.18 | -0.19 | -0.19 |
| Weighted avg. shares (diluted) | 41.87M | 37.79M | 34.84M | 33.12M | 29.10M |
| Balance sheet | |||||
| Cash & equivalents | $74,631 | $22,203 | $222,665 | $93,095 | $241,619 |
| Current assets | — | — | — | $313,767 | $448,839 |
| Total assets | $286,500 | $195,171 | $409,845 | $313,767 | $452,339 |
| Current liabilities | — | — | — | $10.14M | $8.40M |
| Total liabilities | $18.82M | $15.81M | $13.04M | $10.14M | $8.40M |
| Shareholders' equity | -$18.54M | -$15.61M | -$12.63M | -$9.83M | -$7.95M |
| Shares outstanding | 45.04M | 39.83M | 36.08M | 34.36M | 32.54M |
| Cash flow statement | |||||
| Operating cash flow | -$2.68M | -$2.35M | -$3.14M | -$3.38M | -$2.77M |
| Financing cash flow | $2.74M | $2.15M | $3.27M | $3.23M | $2.99M |
| Stock-based compensation | $288,424 | $463,034 | $77,887 | $419,401 | $791,668 |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.